UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

The lancet oncology, 2017-07, Vol.18 (7), p.895-903

2017

Volltextzugriff (PDF)

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2980-2987

2016

Volltextzugriff (PDF)

Biophysical isolation and identification of circulating tumor cells

Lab on a chip, 2017-04, Vol.17 (8), p.1452-1461

2017

Volltextzugriff (PDF)

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Journal of thoracic oncology, 2022-03, Vol.17 (3), p.423-433

2022

Volltextzugriff (PDF)

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

Scientific reports, 2018-02, Vol.8 (1), p.2592-10, Article 2592

2018

Volltextzugriff (PDF)

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

Clinical cancer research, 2016-05, Vol.22 (10), p.2386-2395

2016

Volltextzugriff (PDF)

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

Molecular cancer, 2024-05, Vol.23 (1), p.115-17, Article 115

2024

Volltextzugriff (PDF)

Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

Cancer, 2012-12, Vol.118 (23), p.5903-5911

2012

Volltextzugriff (PDF)

A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1284-1293

2018

Volltextzugriff (PDF)

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

Cancer immunology research, 2018-03, Vol.6 (3), p.288-294

2018

Volltextzugriff (PDF)

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

Frontiers in oncology, 2023-05, Vol.13, p.1178313

2023

Volltextzugriff (PDF)

PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report

BMC nephrology, 2018-08, Vol.19 (1), p.210-210, Article 210

2018

Volltextzugriff (PDF)

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Journal of hematology and oncology, 2017-03, Vol.10 (1), p.73-73, Article 73

2017

Volltextzugriff (PDF)

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management

Therapeutic advances in medical oncology, 2018-01, Vol.10, p.1758834017751634-1758834017751634

2018

Volltextzugriff (PDF)

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Journal of clinical oncology, 2019-10, Vol.37 (28), p.2518-2527

2019

Volltextzugriff (PDF)

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

The New England journal of medicine, 2023-07, Vol.389 (2), p.137-147

2023

Volltextzugriff (PDF)

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723

2020

Volltextzugriff (PDF)

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab -Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer

Frontiers in oncology, 2019-11, Vol.9, p.1256-1256

2019

Volltextzugriff (PDF)

High efficiency vortex trapping of circulating tumor cells

Biomicrofluidics, 2015-11, Vol.9 (6), p.064116-064116

2015

Volltextzugriff (PDF)

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Journal of clinical oncology, 2023-04, Vol.41 (10), p.1830-1840

2023

Volltextzugriff (PDF)

Combination treatment options for small-cell lung cancer – Authors' reply

The lancet oncology, 2021-03, Vol.22 (3), p.e84-e84

2021

Volltextzugriff (PDF)

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

Journal of clinical oncology, 2020-02, Vol.38 (6), p.538-547

2020

Volltextzugriff (PDF)

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100330-100330, Article 100330

2022

Volltextzugriff (PDF)

1 – 25 von 347

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(331)
Mit Volltextzugriff
(295)

Publikationsform

Sprache

Englisch
(345)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(198)
Life Sciences & Biomedicine
(182)
Humans
(154)
Female
(100)
Male
(99)
Oncology
(81)
Middle Aged
(75)
Adult
(68)
Aged
(58)
Lung Neoplasms - Drug Therapy
(39)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(37)
Aged, 80 And Over
(26)
Mutation
(26)
Adolescent
(25)
Biological And Medical Sciences
(25)
Lung Cancer
(24)
Medical Sciences
(24)
Lung Neoplasms - Genetics
(23)
Lung Neoplasms - Pathology
(23)
Patients
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Biophysical isolation and identification of circulating tumor cells

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab -Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer

High efficiency vortex trapping of circulating tumor cells

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Combination treatment options for small-cell lung cancer – Authors' reply

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

Suchergebnisse filtern